学術雑誌論文 <Original article> Assessment of cilostazol inhibition using whole blood samples : comparison of three platelet function tests

Ohta, Masato  ,  Satoh, Kaneo  ,  Fukasawa, Isao  ,  Hosokawa, Kazuya  ,  Oonishi,Tomoko  ,  Nakagomi, Junko  ,  Ozaki, Yukio

32 ( 1 )  , pp.27 - 37 , 2017 , 山梨大学医学会
ISSN:1348-5091
NII書誌ID(NCID):AA11839837
内容記述
Introduction: Cilostazol inhibits phosphodiesterase, with resultant increase in intracellular cyclic AMP, leading to platelet inhibition, particularly in the presence of prostaglandin E1 (PGE1). This study aimed to establish a cilostazol monitoring assay, using whole blood samples.Methods: Platelet aggregation in the presence or absence of indicated concentrations of PGE1 were assessed using VerifyNowR, MultiplateR and Total Thrombus-formation Analysis System (T-TASR).Results: In the presence of added PGE1, cilostazol inhibited in vitro platelet aggregation of VerifyNow, with the aspirin test by 19% and the IIb/IIIa test by 44%, respectively. After a single oral uptake of cilostazol in healthy volunteers, cilostazol decreased platelet aggregation, with the IIb/IIIa test by 46% and with the P2Y12 test by 24%, respectively. Multiplate or T-TAS failed to detect cilostazol effi cacy both in vitro and ex vivo. VerifyNow IIb/IIIa tests were used to monitor cilostazol effi cacy on cerebral infarction patients. Compared with pre-therapy blood samples, those after cilostazol uptake showed signifi cant inhibition of platelet aggregation in the presence of 3 nM (37%) and 10 nM PGE1 (69%).Conclusion: The IIb/IIIa tests of VerifyNow in the presence of 10 nM PGE1 is the most suitable tool for monitoring assessing cilostazol.
本文を読む

http://opac.lib.yamanashi.ac.jp/opac/repository/1/29955/YMJ32-1-027to037.pdf

このアイテムのアクセス数:  回

その他の情報